Author:
Eichler Hans-Georg,Bloechl-Daum Brigitte,Brasseur Daniel,Breckenridge Alasdair,Leufkens Hubert,Raine June,Salmonson Tomas,Schneider Christian K.,Rasi Guido
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference85 articles.
1. European Medicines Agency (EMA). Benefit–risk methodology project. Work package 1 report: description of the current practice of benefit-risk assessment for centralised procedure products in the EU regulatory network. EMA website
[online]
, (2011).
2. Beckman, R. A., Clark, J. & Chen, C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Rev. Drug Discov. 10, 735–748 (2011).
3. Manski, C. Adaptive partial drug approval: a health policy proposal. Economists' Voice 6, 1–5 (2009).
4. Commission of the European Communities. Communication from the commission on the precautionary principle. EC website
[online]
, (2000).
5. Wiener, J. B. Whose precaution after all? A comment on the comparison and evolution of risk regulatory systems. Duke Journal Comparative International Law 13, 207 (2003).
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献